Comparative Study of Efficacy and Safety of Ramipril and Telmisartan on Serum Electrolytes in Newly Diagnosed Hypertensive Patients
- 1. Assistant Professor, Department of Pharmacology, Hind Institute of Medical Sciences, Barabanki, Uttar Pradesh
- 2. Senior Resident, Department of Pharmacology, Hind Institute of Medical Sciences, Barabanki, Uttar Pradesh
- 3. Professor and Head, Department of Pharmacology, DR BR Ambedkar State Institute of Medical Sciences, Mohali, Punjab
Description
Introduction: ACEIs (angiotensin converting enzyme inhibitor) and ARBs (angiotensin II receptor blockers) are two medications that are frequently recommended to treat heart conditions and hypertension. It is now crucial to assess and investigate into how these medications affect the variations in serum electrolytes. Objective: To compare the effects of Ramipril and Telmisartan on blood pressure, serum potassium and serum sodium. Materials and Methods: The prospective study, which lasted 24 weeks and involved patients in the age range of 30 to 60 who had recently been diagnosed with grade 1 hypertension, was carried out at the Department of Pharmacology in collaboration with the Department of Cardiology at a tertiary care teaching hospital. A total of 120 patients completed the research. According to randomization, patients were instructed to take either Ramipril 2.5 mg (Group 1, n = 58) or Telmisartan 40 mg (Group 2, n = 62). The student’s t-test is used for statistical analysis, and all data are expressed as mean ±SD. Results: At the fourth follow-up visit, or 24 weeks, there is a significant (p<0.001) decrease in mean SBP and mean DBP compared to the baseline visit for both groups 1 (Ramipril) and 2 (Telmisartan). However, when group 1 and group 2 are compared at the fourth visit, there is no statistically significant difference in mean SBP and mean DBP (p>0.05). In relation to serum electrolytes, there was no significant difference between baseline and fourth visit in group 1 in serum potassium (4.00 ± 0.54 to 4.07 ± 0.53) and serum sodium (139.00 ± 5.67 to 138.3 ± 5.17). Similarly, between the baseline visit and the fourth visit in group 2, there was also not a significant difference in the serum potassium (4.15 ± 0.55 to 4.17 ± 0.52) or sodium (137.74 ± 5.41 to 137.45 ± 7.74) (p>0.05). Additionally, it was found that there was no statistically significant difference between the two groups’ mean serum potassium and mean serum sodium at the fourth visit (p>0.05). Conclusion: Our study’s conclusion is that the antihypertensive efficaciousness of Telmisartan and Ramipril as monotherapy is nearly equal and regarding safety the both medications have minimal effects on serum potassium and sodium levels. For a period of six months, it indicates a lower risk of cardiac and other issues associated to hyperkalemia and hyponatremia. But before prescribing the medication, especially to an elderly patient, one must carefully assess their comorbid illnesses, and should be closely monitored for potassium and sodium levels.
Abstract (English)
Introduction: ACEIs (angiotensin converting enzyme inhibitor) and ARBs (angiotensin II receptor blockers) are two medications that are frequently recommended to treat heart conditions and hypertension. It is now crucial to assess and investigate into how these medications affect the variations in serum electrolytes. Objective: To compare the effects of Ramipril and Telmisartan on blood pressure, serum potassium and serum sodium. Materials and Methods: The prospective study, which lasted 24 weeks and involved patients in the age range of 30 to 60 who had recently been diagnosed with grade 1 hypertension, was carried out at the Department of Pharmacology in collaboration with the Department of Cardiology at a tertiary care teaching hospital. A total of 120 patients completed the research. According to randomization, patients were instructed to take either Ramipril 2.5 mg (Group 1, n = 58) or Telmisartan 40 mg (Group 2, n = 62). The student’s t-test is used for statistical analysis, and all data are expressed as mean ±SD. Results: At the fourth follow-up visit, or 24 weeks, there is a significant (p<0.001) decrease in mean SBP and mean DBP compared to the baseline visit for both groups 1 (Ramipril) and 2 (Telmisartan). However, when group 1 and group 2 are compared at the fourth visit, there is no statistically significant difference in mean SBP and mean DBP (p>0.05). In relation to serum electrolytes, there was no significant difference between baseline and fourth visit in group 1 in serum potassium (4.00 ± 0.54 to 4.07 ± 0.53) and serum sodium (139.00 ± 5.67 to 138.3 ± 5.17). Similarly, between the baseline visit and the fourth visit in group 2, there was also not a significant difference in the serum potassium (4.15 ± 0.55 to 4.17 ± 0.52) or sodium (137.74 ± 5.41 to 137.45 ± 7.74) (p>0.05). Additionally, it was found that there was no statistically significant difference between the two groups’ mean serum potassium and mean serum sodium at the fourth visit (p>0.05). Conclusion: Our study’s conclusion is that the antihypertensive efficaciousness of Telmisartan and Ramipril as monotherapy is nearly equal and regarding safety the both medications have minimal effects on serum potassium and sodium levels. For a period of six months, it indicates a lower risk of cardiac and other issues associated to hyperkalemia and hyponatremia. But before prescribing the medication, especially to an elderly patient, one must carefully assess their comorbid illnesses, and should be closely monitored for potassium and sodium levels.
Files
IJPCR,Vol16,Issue5,Article31.pdf
Files
(578.3 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:f0a4efa8dd5b61ae523d0fa0308dcfe6
|
578.3 kB | Preview Download |
Additional details
Dates
- Accepted
-
2024-04-26
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/16/IJPCR,Vol16,Issue5,Article31.pdf
- Development Status
- Active
References
- 1. World Health Organization, "A global brief on Hypertension, silent killer, global public health crisis. 2013," 2014, http://apps.who.int/iris/ bitstream/10665/79059/1/WHO DCO WHD 2013.2 eng.pdf 2. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin- converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000; 342: 145–153. 3. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345: 861– 869. 4. Ushio-Yamana H, Minegishi S, Ishigami T, Araki N, Umemura M, Tamura K, et al. Renin angiotensin antagonists normalize aberrant activation of epithelial sodium channels in sodium-sensitive hypertension. Nephron Exp Nephrol. 2012; 122:95-102. 5. Cakir M. Significant hyperkalemia and hyponatremia secondary to telmisartan/ hydrochlorothiazide treatment. Blood Press. 2010; 19: 380-2. 6. Yawar A, Jabbar A, Haque NU, Zuberi LM, Islam N, Akhtar J. Hyponatraemia: Etiology, management and outcome. J Coll Physicians Surg Pak. 2008; 18:467-71. 7. Rardon DP and Fisch C. Electrolytes and the heart, 8th ed. New York: McGraw Hill Book Co., 1994. 8. Lambers Heerspink HJ, Gao P, de Zeeuw D et al.The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: Results from the ONTARGET trial. European Journal of Preventive Cardiology 2014;21(3):299–309. 9. J Petrovic, D Petrovic, N Vukovic et al. Ventricular and Vascular Remodelling – Effects of the Angiotensin II Receptor Blocker Telmisartan and/or the Angiotensin-converting Enzyme Inhibitor Ramipril in Hypertensive Patients. 2005 JIMR; 33 (Suppl 1): 39A – 49A. 10. Christian Delles et al. Effects of Telmisartan and Ramipril on Adiponectin and Blood Pressure in Patients with Type 2 Diabetes American Journal of Hypertension, 2008; 21(12): 1330–1336. 11. Lacourcière Y, Neutel J.M, Davidai G, Koval S. A Multicenter, 14-Week Study of Telmisartan and Ramipril in Patients With Mild-toModerate Hypertension Using Ambulatory Blood Pressure Monitoring AJH 2006; 19: 104–112 12. White WB: Relevance of blood pressure variation in the circadian onset of cardiovascular events. J Hypertens. 2003; 21 (Suppl 6): S9 – S15. 13. Bhuvaneshwari S, Saroj PV, Vijaya D, Sowmya MS, Kumar RS. Hyponatremia induced by angiotensin converting enzyme in-hibitors and angiotensin receptor blockers-a pilot study. J Clin Diagn Res 2018; 12:FC01-3. 14. Pratibha S. Salve1, Chitra C. Khanwelkar, Preeti S. Salve, Vandana M. Thorat, Somnath M. Matule. Effects of angiotensin converting enzyme inhibitor: ramipril on different biochemical parameters in essential hypertensive patients. Int J Res Med Sci. 2016 Jun; 4(6):2288-2291 15. Kinoshita H, Kobayashi K, Yaguramaki T, Yasuda M, Fujiki K, Tomiyama J, et al. Losartan potassium/hydrochlorothiazide (Preminent®) and hyponatremia: Case series of 40 patients. Hum exp Toxicol 2011; 30:1409-14. 16. Aranda P, Segura J, Ruilope LM, et al. Longterm renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies. Am J Kidney Dis. 2005; 46:1074–1079. 17. Sadjadi SA, McMillan JI, Jaipaul N, Blakely P, Hline SS. A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers. Ther Clin Risk Manag. 2009; 5:547 – 552. 18. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358:1547 – 1559. 19. Yusuf S et al. Effects of the angiotensinreceptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors. Lancet. 2008 Sep 27; 372(9644):1174-83.